Literature DB >> 28450060

Endocannabinoid modulation of dopamine neurotransmission.

Dan P Covey1, Yolanda Mateo2, David Sulzer3, Joseph F Cheer4, David M Lovinger5.   

Abstract

Dopamine (DA) is a major catecholamine neurotransmitter in the mammalian brain that controls neural circuits involved in the cognitive, emotional, and motor aspects of goal-directed behavior. Accordingly, perturbations in DA neurotransmission play a central role in several neuropsychiatric disorders. Somewhat surprisingly given its prominent role in numerous behaviors, DA is released by a relatively small number of densely packed neurons originating in the midbrain. The dopaminergic midbrain innervates numerous brain regions where extracellular DA release and receptor binding promote short- and long-term changes in postsynaptic neuron function. Striatal forebrain nuclei receive the greatest proportion of DA projections and are a predominant hub at which DA influences behavior. A number of excitatory, inhibitory, and modulatory inputs orchestrate DA neurotransmission by controlling DA cell body firing patterns, terminal release, and effects on postsynaptic sites in the striatum. The endocannabinoid (eCB) system serves as an important filter of afferent input that acts locally at midbrain and terminal regions to shape how incoming information is conveyed onto DA neurons and to output targets. In this review, we aim to highlight existing knowledge regarding how eCB signaling controls DA neuron function through modifications in synaptic strength at midbrain and striatal sites, and to raise outstanding questions on this topic. This article is part of the Special Issue entitled "A New Dawn in Cannabinoid Neurobiology".
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cannabinoids; Dopamine; Endocannabinoids; Nucleus accumbens; Striatum

Mesh:

Substances:

Year:  2017        PMID: 28450060      PMCID: PMC5608040          DOI: 10.1016/j.neuropharm.2017.04.033

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  142 in total

1.  Cannabinoid receptor agonists inhibit Ca current in NG108-15 neuroblastoma cells via a pertussis toxin-sensitive mechanism.

Authors:  M P Caulfield; D A Brown
Journal:  Br J Pharmacol       Date:  1992-06       Impact factor: 8.739

2.  Vesicular dopamine release elicits an inhibitory postsynaptic current in midbrain dopamine neurons.

Authors:  Michael J Beckstead; David K Grandy; Kevin Wickman; John T Williams
Journal:  Neuron       Date:  2004-06-24       Impact factor: 17.173

3.  Endocannabinoid regulation of relapse mechanisms.

Authors:  Liana Fattore; Paola Fadda; Walter Fratta
Journal:  Pharmacol Res       Date:  2007-09-08       Impact factor: 7.658

Review 4.  Shaping action sequences in basal ganglia circuits.

Authors:  Xin Jin; Rui M Costa
Journal:  Curr Opin Neurobiol       Date:  2015-07-17       Impact factor: 6.627

5.  [3H]dihydrotetrabenazine, a new in vitro monoaminergic probe for human brain.

Authors:  D Scherman; R Raisman; A Ploska; Y Agid
Journal:  J Neurochem       Date:  1988-04       Impact factor: 5.372

Review 6.  G protein-coupled receptors--recent advances.

Authors:  Dorota Latek; Anna Modzelewska; Bartosz Trzaskowski; Krzysztof Palczewski; Sławomir Filipek
Journal:  Acta Biochim Pol       Date:  2012-12-18       Impact factor: 2.149

7.  Cannabinoid receptor localization in brain.

Authors:  M Herkenham; A B Lynn; M D Little; M R Johnson; L S Melvin; B R de Costa; K C Rice
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

Review 8.  Reward and aversion in a heterogeneous midbrain dopamine system.

Authors:  Stephan Lammel; Byung Kook Lim; Robert C Malenka
Journal:  Neuropharmacology       Date:  2013-04-08       Impact factor: 5.250

9.  Cholinergic interneurons mediate fast VGluT3-dependent glutamatergic transmission in the striatum.

Authors:  Michael J Higley; Aryn H Gittis; Ian A Oldenburg; Nina Balthasar; Rebecca P Seal; Robert H Edwards; Bradford B Lowell; Anatol C Kreitzer; Bernardo L Sabatini
Journal:  PLoS One       Date:  2011-04-22       Impact factor: 3.240

Review 10.  Local control of striatal dopamine release.

Authors:  Roger Cachope; Joseph F Cheer
Journal:  Front Behav Neurosci       Date:  2014-05-23       Impact factor: 3.558

View more
  43 in total

Review 1.  Evidence for the use of cannabinoids in Parkinson's disease.

Authors:  Carsten Buhmann; Tina Mainka; Georg Ebersbach; Florin Gandor
Journal:  J Neural Transm (Vienna)       Date:  2019-05-27       Impact factor: 3.575

2.  Mechanism for differential recruitment of orbitostriatal transmission during actions and outcomes following chronic alcohol exposure.

Authors:  Rafael Renteria; Christian Cazares; Emily T Baltz; Drew C Schreiner; Ege A Yalcinbas; Thomas Steinkellner; Thomas S Hnasko; Christina M Gremel
Journal:  Elife       Date:  2021-03-17       Impact factor: 8.140

3.  Inhibition of endocannabinoid degradation rectifies motivational and dopaminergic deficits in the Q175 mouse model of Huntington's disease.

Authors:  Dan P Covey; Hannah M Dantrassy; Samantha E Yohn; Alberto Castro; P Jeffrey Conn; Yolanda Mateo; Joseph F Cheer
Journal:  Neuropsychopharmacology       Date:  2018-06-01       Impact factor: 7.853

4.  Genetic Predisposition vs Individual-Specific Processes in the Association Between Psychotic-like Experiences and Cannabis Use.

Authors:  Nicole R Karcher; Deanna M Barch; Catherine H Demers; David A A Baranger; Andrew C Heath; Michael T Lynskey; Arpana Agrawal
Journal:  JAMA Psychiatry       Date:  2019-01-01       Impact factor: 21.596

5.  The roles of cannabinoid CB1 and CB2 receptors in cocaine-induced behavioral sensitization and conditioned place preference in mice.

Authors:  Jadna B Lopes; Juliana R Bastos; Rayssa B Costa; Daniele C Aguiar; Fabrício A Moreira
Journal:  Psychopharmacology (Berl)       Date:  2019-10-30       Impact factor: 4.530

6.  Cannabinoid receptor-1 signaling contributions to sign-tracking and conditioned reinforcement in rats.

Authors:  Sam Z Bacharach; Helen M Nasser; Natalie E Zlebnik; Hannah M Dantrassy; Daniel E Kochli; Utsav Gyawali; Joseph F Cheer; Donna J Calu
Journal:  Psychopharmacology (Berl)       Date:  2018-08-14       Impact factor: 4.530

7.  Acute effects of cannabinoids on symptoms of obsessive-compulsive disorder: A human laboratory study.

Authors:  Reilly R Kayser; Margaret Haney; Marissa Raskin; Caroline Arout; Helen Blair Simpson
Journal:  Depress Anxiety       Date:  2020-05-07       Impact factor: 6.505

Review 8.  Possible actions of cannabidiol in obsessive-compulsive disorder by targeting the WNT/β-catenin pathway.

Authors:  Alexandre Vallée; Yves Lecarpentier; Jean-Noël Vallée
Journal:  Mol Psychiatry       Date:  2021-04-09       Impact factor: 15.992

Review 9.  Which came first: Cannabis use or deficits in impulse control?

Authors:  Linda Rinehart; Sade Spencer
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2020-08-11       Impact factor: 5.067

10.  Chronic cannabinoid exposure produces tolerance to the dopamine releasing effects of WIN 55,212-2 and heroin in adult male rats.

Authors:  Devan M Gomez; Thomas J Everett; Lindsey R Hamilton; Ajit Ranganath; Joseph F Cheer; Erik B Oleson
Journal:  Neuropharmacology       Date:  2020-10-25       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.